Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

distribution. 50% of the values are above and 50% below the median.

Monotherapy: treatment with one drug as opposed to combination therapy. Here the term refers to treatment with CYT003-QbG10 alone in contrast to a regimen where CYT003-QbG10 is combined to an allergen extract.

Open-label: a set-up used in clinical trials where the doctor and the patient know what substance is administered; in contrast to e.g. double-blind, placebo-controlled studies, where neither the doctor nor the patient have this knowledge.

Phase IIa: a clinical trial that examines a new drug candidate’s safety and exploratory efficacy and may include between 10 and 100 patients.

Placebo: dummy medical treatment.

QbG10: Cytos Biotechnology’s Immunodrug™ Qb filled with the immunostimulatory DNA sequence G10.

Regimen: describes a treatment schedule according to which a drug is administered.

Th1 and Th2 type immune responses: describe T helper cell responses. T helper cells are a subset of T cells that secrete a variety of mediators (cytokines) playing a role for other immune cells. A Th1 type immune response is usually induced by viral or bacterial infection, or also by potent vaccination / immunotherapy. A Th2 type immune response usually manifests an allergic reaction.

About Cytos Biotechnology AG

Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T-cell responses that modulate chronic disease process
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014  Millions of ... of cervical disc disease. Recently the FDA ... artificial cervical disc, an innovative implant device developed by Spinal ... herniations resulting in neck and or arm pain. Hospital for ... nation, is the only hospital in New York ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
(Date:9/17/2014)... R.I. , Sept. 17, 2014 An ... insights regarding patients taking Sovaldi® (sofosbuvir), a new and ... data shows that over the last several months (May ... actual downward trend in Sovaldi utilization. This suggests another ... of new therapeutic regimens of similar efficacy and shorter ...
Breaking Medicine Technology:Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Hamamatsu Corporation has announced the release of its next-generation slide ... speed of the original series, the NanoZoomer 2.0 converts a ... into a 1.9-gigapixel color image in as little as 1 ... viewed on a computer monitor, shared across computer networks, used ...
... Entity to Address Workforce , WASHINGTON, Oct. ... staff and representatives of national health care organizations ... legislation does not yet reflect the strategic emphasis ... system reform. "Pending bills include numerous important ...
Cached Medicine Technology:New 'Virtual Microscope' System from Hamamatsu Offers Faster Acquisition of High-Resolution Slide Scans 2Health Reform Bills Still Lack Strategic Focus on Health Workforce 2
(Date:9/18/2014)... 18, 2014 INDIGO Biosciences, a leading ... that it has released a new Human Estrogen-related Orphan ... kits are available. , ERR? is naturally expressed in ... in a variety of other tissue types, including kidney, ... a potential target for anti-obesity therapeutics. Cross-talk between ...
(Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
(Date:9/18/2014)... September 18, 2014 Dentists from ... of highly acclaimed Oxnard All-on-4™ dental implants ... a prosthodontist from the Anacapa Dental Art Institute ... the Canadian Academy of Restorative Dentistry and Prosthodontics ... Reshad’s presentation, “Resection Versus Augmentation: Esthetic Implant Supported ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... Fla (PRWEB) September 18, 2014 According to ... suffer from eczema, with many of them being children. In ... first diagnosed as babies and children. The millions of children ... can be brought on by eczema. A new book has ... who they are and to find relief from the condition ...
Breaking Medicine News(10 mins):Health News:INDIGO Offers Human Estrogen-related Receptor Gamma Assay System 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... XP Electroanatomical Mapping System combines the legendary ... operating ease of Windows* software. It ... powerful new tools that enhance your clinical ... you into the future of EP. ...
... pulse generators are meeting the clinical ... electrophysiologists and anesthesiologists. And, they are ... expect from Medtronic.,Effective pacing with the ... polarity for quick battery changes. ...
... is a unique left ventricular assist device that ... is being used in a small group of ... part of an FDA-approved Feasibility Study. The patient ... external power source for minutes or hours. The ...
... introduced the world's first minimally-invasive epicardial lead ... Lead Implant Tool, which has been cleared ... expand the options available to implanting physicians ... on the heart during pacemaker implants. The ...
Medicine Products: